Table 2 Reporting by Member States on routine surveillance of viral hepatitis B and C
World Health Organization European sub-region | Total | |||
|---|---|---|---|---|
West | Centre | East | ||
N = 18 (%) | N = 13 (%) | N = 13 (%) | N = 44 (%) | |
National surveillance system for acute HBV: | ||||
yes | 17 (94.4) | 13 (100) | 13 (100) | 43 (97.3) |
no | 1 (5.6) | 0 (0) | 0 (0) | 1 (2.3) |
National surveillance system for acute HCV: | ||||
yes | 15 (83.3) | 13 (100) | 13 (100) | 41 (93.2) |
no | 3 (16.7) | 0 (0) | 0 (0) | 3 (6.8) |
National surveillance system for chronic HBV: | ||||
yes | 11 (61.1) | 7 (53.8) | 10 (76.9) | 28 (63.6) |
no | 7 (38.9) | 6 (46.2) | 3 (23.1) | 16 (36.4) |
National surveillance system for chronic HCV: | ||||
yes | 10 (55.6) | 7 (53.8) | 10 (76.9) | 27 (61.4) |
no | 8 (44.4) | 6 (46.2) | 3 (23.1) | 17 (38.6) |
Standard case definitions for viral hepatitis infections: | ||||
yes | 17 (94.4) | 13 (100) | 12 (92.3) | 42 (95.5) |
no | 1 (5.6) | 0 (0) | 1 (7.7) | 2 (4.5) |
% of hepatitis cases reported as “undifferentiated” or “unclassified”: | ||||
zero | 6 (33.3) | 2 (15.4) | 2 (15.4) | 10 (22.7) |
less than 5 % | 2 (11.1) | 4 (30.8) | 3 (23.1) | 9 (20.5) |
5–15 % | 0 (0) | 2 (15.4) | 3 (23.1) | 5 (11.4) |
more than 15 % | 1 (5.6) | 2 (15.4) | 1 (7.1) | 4 (9.1) |
no response | 9 (50.0) | 3 (23.1) | 4 (30.8) | 16 (36.4) |
Adequate laboratory capacity nationally to support hepatitis outbreak investigations and other surveillance activities for HBV and HBC: | ||||
yes | 18 (100) | 13 (100) | 13 (100) | 44 (100) |
Hepatitis outbreaks required to be reported to the government and further investigated: | ||||
yes | 17 (94.4) | 13 (100) | 12 (92.3) | 42 (95.5) |
no | 1 (5.6) | 0 (0) | 1 (7.7) | 2 (4.5) |
Hepatitis disease reports published regularly (at least once per year): | ||||
yes | 15 (83.3) | 13 (100) | 11 (84.6) | 39 (88.6) |
no | 3 (16.7) | 0 (0) | 2 (15.4) | 5 (11.4) |